• Kardigan expects Phase 2b topline data for tonlamarsen in acute severe hypertension in the first half of 2027.
• Danicamtiv’s Phase 2b readout in genetic dilated cardiomyopathy is expected in the first half of 2027; enrollment targets approximately 80 patients.
• Ataciguat’s Phase 2b trial in aortic stenosis has completed enrollment, with 48-week interim data expected in the second half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kardigan Inc. published the original content used to generate this news brief on November 06, 2026, and is solely responsible for the information contained therein.